Canada markets open in 7 hours 41 minutes
  • S&P/TSX

    20,156.36
    +156.77 (+0.78%)
     
  • S&P 500

    4,224.79
    +58.34 (+1.40%)
     
  • DOW

    33,876.97
    +586.89 (+1.76%)
     
  • CAD/USD

    0.8080
    -0.0012 (-0.15%)
     
  • CRUDE OIL

    73.63
    -0.03 (-0.04%)
     
  • BTC-CAD

    40,374.27
    -2,226.28 (-5.23%)
     
  • CMC Crypto 200

    783.61
    -66.73 (-7.85%)
     
  • GOLD FUTURES

    1,781.30
    -1.60 (-0.09%)
     
  • RUSSELL 2000

    2,286.09
    +48.35 (+2.16%)
     
  • 10-Yr Bond

    1.4840
    0.0000 (0.00%)
     
  • NASDAQ futures

    14,137.50
    +7.50 (+0.05%)
     
  • VOLATILITY

    17.89
    -2.81 (-13.57%)
     
  • FTSE

    7,062.29
    +44.82 (+0.64%)
     
  • NIKKEI 225

    28,809.20
    +798.27 (+2.85%)
     
  • CAD/EUR

    0.6785
    0.0000 (0.00%)
     

Aurinia Pharmaceuticals to Participate in Two Upcoming Investor Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the "Company") today announced that members of the executive management team will participate in two upcoming investor conferences:

  • RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021 at 10:55 a.m. ET; and

  • Oppenheimer Rare & Orphan Disease Summit on Friday, May 21, 2021 at 10:45 a.m. ET.

In order to participate in the audio webcast, interested parties can access the live webcast under "News/Events" through the "Investors" section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia’s website.

ABOUT AURINIA

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company has introduced LUPKYNIS™ (voclosporin), the first FDA-approved oral therapy dedicated for the treatment of adult patients with active lupus nephritis (LN). The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210514005073/en/

Contacts

Investor Contact:
Glenn Schulman, PharmD, MPH
SVP, Corporate Communications & IR
gschulman@auriniapharma.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting